FlyteHealth Expands Medicare Care Through CMS Platform
NEW CANAAN, Conn., July 28, 2026 FlyteHealth has achieved General Availability within the Centers for Medicare & Medicaid Services...
Insulin Resistance
Advertisement
Aqua Medical Treats First U.S. Patient in Diabetes Trial
PLEASANTON, Calif., July 28, 2026 Aqua Medical, Inc. has achieved a major clinical milestone with the successful treatment of...
HERVolution Reports HERV-K Findings in Obesity Research
COPENHAGEN, Denmark & NEW YORK, USA, July 15, 2026 HERVolution Therapeutics ApS, a biotechnology company developing human endogenous retrovirus...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Caliway Presents CBL-514 Data Showing Reduced Weight Regain with GLP-1 Therapies
June 10, 2026 – Taipei, Taiwan Caliway Biopharmaceuticals announced new preclinical data demonstrating the potential of its proprietary fat-reduction...
Advertisements
Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity
COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...
Cirius Therapeutics Highlights CIR-0602K as Promising New Therapy for Type 2 Diabetes
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
Advertisement
